Evidence map›Paper›PMID 42196914›Full record

ReviewDiagnostics (Basel, Switzerland)2026

Beyond the Tipping Point: Advances in the Diagnosis and Management of Acute-on-Chronic Liver Failure and End-Stage Liver Disease.

Jonathan Soldera

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jonathan SolderaPGDip and MSc Acute Medicine and Gastroenterology, University of South Wales in Association with Learna Ltd., Cardiff CF37 1DL, UK.ORCID 0000-0001-6055-4783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute-on-chronic liver failure (ACLF) is the point at which cirrhosis stops behaving as a chronic liver disease and becomes a rapidly destabilising systemic illness. It is the real tipping point in advanced liver disease: the moment when limited hepatic reserve is no longer the only issue, and the clinical picture is instead defined by systemic inflammation, extrahepatic organ dysfunction, and a high risk of short-term death. This has changed how we understand the natural history of cirrhosis. Rather than a simple linear progression toward liver failure, advanced chronic liver disease is now better seen as a dynamic continuum that may lead to first decompensation, recurrent decompensation, ACLF, end-stage disease, or, in selected cases, recompensation if the underlying driver is effectively controlled. This shift matters because patients with ACLF are not simply "sicker cirrhotics". They are in a distinct pathophysiological state, marked by inflammation, circulatory dysfunction, immune dysregulation, and organ cross-talk that extends beyond the liver. In this setting, the boundaries between liver failure, sepsis, renal dysfunction, and critical illness become blurred, which is why ACLF remains such a difficult syndrome to manage. At the same time, recent guidance has improved the approach to decompensated cirrhosis, HRS-AKI, infection, transplantation, and palliative care, while newer consensus efforts have tried to reduce differences between ACLF definitions. In practice, management still depends on simple but disciplined principles: early recognition, rapid identification of precipitants, parallel organ support, prompt treatment of infection and HRS-AKI, repeated reassessment, and urgent transplant evaluation when appropriate. This review examines ACLF and end-stage liver disease as interconnected stages of advanced cirrhosis and discusses how care can be both aggressive when recovery is possible and humane when recovery is not.

Indexed as

acute-on-chronic liver failureend stage liver diseasehepatorenal syndromeliver cirrhosisliver transplantation

Identifiers

PMID42196914
PMCPMC13205394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.